How To Successfully Strategize Real World Evidence For Market Access
Payers and clinicians increasingly want to know how products work in real life, especially when data is limited. Real world evidence can help companies argue a product's value, but they should think carefully about their strategies as challenges remain.
You may also be interested in...
Efficacy Studies Not Enough? Consider GSK's Salford Lung Study As New Model
Full results from asthma patients included in the Salford Lung Study provide powerful support for the use of “real world” effectiveness studies as a more relevant form of evidence to inform prescribing choices and improve patient outcomes, particularly in what turned out to be a general population of asthmatics that were still suffering symptoms under usual care.
Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
Q&A: Pfizer On Unlocking The Promise Of Real World Evidence
Real world evidence offers big potential to get medicines to the market, but exploiting the data is not always easy for companies. Pfizer's James Harnett explains the firm's RWE strategy and some of the challenges, like unstructured data and the need for incentives and standards for gathering the data.